Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence

Not Applicable

Completed

• Conditions: Stress Urinary Incontinence
• Interventions: Device: Viveve - Active; Device: Viveve - Cryogen-Alone; Device: Viveve - Sham

• Registration Number: NCT04206085
• Lead Sponsor: Viveve Inc.

Brief Summary

This is a prospective, randomized, single-blind, study comparing both the Viveve Treatment (RF plus cryogen) and cryogen alone treatment versus sham treatment in patients with mild to moderate stress urinary incontinence.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-12-10
• Study First Submitted QC: 2019-12-17
• Study First Posted: 2019-12-20
• Study Start: 2020-01-01
• Status Verified: 2020-05
• Primary Completion: 2020-08-30
• Study Completion: 2020-08-30
• Results First Submitted: 2022-06-02
• Results First Submitted QC: 2022-08-25
• Last Update Submitted: 2022-08-25
• Results First Posted: 2022-09-21
• Last Update Posted: 2022-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 38

Inclusion Criteria

• Pre-menopausal females, ≥ 18 years of age. Premenopausal is defined as a woman who has had menstrual cycles over the previous 12 months.
• Subjects with a BMI of ≤ 35 kg/m².
• 1-hr pad weight at Baseline with a 5 to 50 g net increase from the pre-test pad weight

Exclusion Criteria

• Subjects who are currently breastfeeding or have discontinued breastfeeding fewer than 6 months prior to screening.
• Subjects who are pregnant or plan to become pregnant during the course of the study.
• Subjects who have undergone other stress urinary incontinence treatments, excluding behavioral modifications (e.g., Kegel exercises).
• Has any implantable electrical device [e.g., implantable pacemaker, automatic implantable cardioverter-defibrillator (AICD)].
• Subjects who have started or changed dose of local vaginal hormones <6 weeks before Screening.
• Subjects who have started pelvic floor physical therapy within the last 3 months.
• Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal (including the Viveve Treatment or any other genital radiofrequency treatment; injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement procedure, and previous dilation and cuterage within 12 months of the subject's Pre-Screening Visit).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active treatment	Viveve - Active	Radiofrequency and Cryogen
Cryogen-Only	Viveve - Cryogen-Alone	Crygen-Only
Sham	Viveve - Sham	Sham comparator

Primary Outcome Measures

Name	Time	Method
1-hour Pad Weight Test	Change in 1 hour Pad Weight Test Values at 5 Months from Baseline	Brief description of test: * Subject puts on one standardized, pre-weighed pad without voiding.; * Subject drinks 500 mL of sodium-free liquid in \< 15 min while sitting or resting.; • 15 - 45 Minutes: * Subject walks for 30 minutes, including climbing one flight of stairs (up and down).; • 45 - 60 Minutes: * Subject performs the following activities Standing up from sitting (10 times) Coughing vigorously (10 times) (Subject should be standing) Running on the spot (1 min) Bending to pick up an object from the floor (5 times) • The weight of the pad is measured to determine the amount of leakage.

Trial Locations

Locations (3)

Milestone Research; 🇨🇦 London, Ontario, Canada

Bluewater Clinical Research Group; 🇨🇦 Sarnia, Ontario, Canada

Devonshire Clinical Research; 🇨🇦 Woodstock, Ontario, Canada